Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics and Abbott Enter Broad Drug-Discovery Collaboration

NEW YORK, April 11 (GenomeWeb News) - Myriad Genetics and Abbott said today that they have entered into a "broad drug-discovery collaboration" to identify unspecified therapeutic targets of interest.

 

The five-year research agreement calls for Myriad to use its RNA expression profiling and "other technologies" to identify human genes and regulatory networks associated with a variety of diseases, the companies said.

 

Abbott will then advance these genes through to its chemical genomics platform to identify targets and leads for drug discovery.

 

Each company will have exclusive rights to the therapeutic targets and drug lead compounds, with Myriad receiving rights to approximately 40 percent of the targets, and Abbott receiving rights to approximately 60 percent, the companies said.

 

It is unclear whether the new collaboration is related to a pharmacogenomics collaboration started between the companies in January 2004, and extended in November 2005.

 

Myriad and Abbott officials could not be reached for comment.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.